Canadian Journal of Cardiology

The Residual Lipid-rich Coronary Atheroma behind the Implanted Newer-generation Drug-eluting Stent and Future Stent-related Event’s Risks



      Lipid-rich plaque is an important substrate that causes future coronary events. However, the clinical implications of underlying plaque characteristics in coronary lesions after newer-generation drug-eluting stent (DES) implantation remain unknown.


      The current study analyzed 445 target lesions after newer-generation DES implantation in 416 patients with CAD (CCS/ACS=264/181) from the REASSURE-NIRS multi-center registry. Near-infrared spectroscopy (NIRS) imaging was used to evaluate maximum lipid core burden index after stent implantation in target lesions (residual maxLCBI4mm). The primary and secondary outcomes were 3-year lesion-oriented clinical outcomes (LOCO; cardiac death, non-fatal target lesion-related MI, or ischemia-driven TLR) and patient-oriented clinical outcomes (POCO; all-cause death, non-fatal MI, or ischemia-driven unplanned revascularization). Outcomes were compared by residual maxLCBI4mm tertile.


      Median residual maxLCBI4mm was 183; 16% of lesions had residual maxLCBI4mm >400. Higher residual maxLCBI4mm was not associated with a greater likelihood of LOCO or POCO during the observational period (LOCO, log-rank p=0.76; POCO, log-rank p=0.84). Mixed-effects logistic regression demonstrated that residual maxLCBI4mm does not predict LOCO (odds ratio=1.000, 95% CI=0.997–1.003, p=0.95). There was no significant relationship between residual maxLCBI4mm and POCO (odds ratio=1.001, 95% CI=0.999–1.002, p=0.30).


      Residual maxLCBI4mm is not associated with LOCO or POCO in patients with CAD after newer-generation DES implantation. Our findings suggest that NIRS-derived underlying lipid-rich plaque is not associated with the risk of stent-related events and patient-based outcomes in patients with CAD who have received a newer-generation DES.

      Graphical abstract



      ACS (acute coronary syndrome), BMS (bare-metal stent), CAD (coronary artery disease), CCS (chronic coronary syndrome), DES (drug-eluting stent), ID-TLR (ischemia-driven target lesion revascularization), IVUS (intravascular ultrasound), LCBI (lipid core burden index), LDL-C (low-density lipoprotein cholesterol), LOCO (lesion-oriented clinical outcome), MI (myocardial infarction), MLD (minimum lumen diameter), MSA (minimum stent area), NIRS (near-infrared spectroscopy), OCT (optical coherence tomography), PCI (percutaneous coronary intervention), %DS (percent diameter stenosis), POCO (patient-oriented clinical outcome), QCA (quantitative coronary angiography)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Canadian Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Yamamoto M.
        • Okamatsu K.
        • Inami S.
        • et al.
        Relationship between neointimal coverage of sirolimus-eluting stents and lesion characteristics: a study with serial coronary angioscopy.
        Am Heart J. 2009; 158: 99-104
        • Hoshino M.
        • Yonetsu T.
        • Kanaji Y.
        • et al.
        Impact of baseline plaque characteristic on the development of neoatherosclerosis in the very late phase after stenting.
        J Cardiol. 2019; 74: 67-73
        • Nakazawa G.
        • Otsuka F.
        • Nakano M.
        • et al.
        The pathology of neoatherosclerosis in human coronary implants bare-metal and drug-eluting stents.
        J Am Coll Cardiol. 2011; 57: 1314-1322
        • Otsuka F.
        • Byrne R.A.
        • Yahagi K.
        • et al.
        Neoatherosclerosis: overview of histopathologic findings and implications for intravascular imaging assessment.
        Eur Heart J. 2015; 36: 2147-2159
        • Gardner C.M.
        • Tan H.
        • Hull E.L.
        • et al.
        Detection of lipid core coronary plaques in autopsy specimens with a novel catheter-based near-infrared spectroscopy system.
        JACC Cardiovasc Imaging. 2008; 1: 638-648
        • Kataoka Y.
        • Puri R.
        • Andrews J.
        • et al.
        In vivo visualization of lipid coronary atheroma with intravascular near-infrared spectroscopy.
        Expert Rev Cardiovasc Ther. 2017; 15: 775-785
        • Goldstein J.A.
        • Maini B.
        • Dixon S.R.
        • et al.
        Detection of lipid-core plaques by intracoronary near-infrared spectroscopy identifies high risk of periprocedural myocardial infarction.
        Circ Cardiovasc Interv. 2011; 4: 429-437
        • Nishihira K.
        • Otsuka F.
        • Kataoka Y.
        • et al.
        Embolization of Neoatherosclerosis After Percutaneous Coronary Intervention: Insights From Near-Infrared Spectroscopy Imaging and Histopathological Analysis.
        Circ Cardiovasc Interv. 2018; 11e006175
        • Zhang J.
        • Gao X.
        • Kan J.
        • et al.
        Intravascular Ultrasound Versus Angiography-Guided Drug-Eluting Stent Implantation: The ULTIMATE Trial.
        J Am Coll Cardiol. 2018; 72: 3126-3137
        • Nicholls S.J.
        • Tuzcu E.M.
        • Sipahi I.
        • Schoenhagen P.
        • Nissen S.E.
        Intravascular ultrasound in cardiovascular medicine.
        Circulation. 2006; 114: e55-59
        • Sonoda S.
        • Morino Y.
        • Ako J.
        • et al.
        Impact of final stent dimensions on long-term results following sirolimus-eluting stent implantation: serial intravascular ultrasound analysis from the sirius trial.
        J Am Coll Cardiol. 2004; 43: 1959-1963
        • Murai K.
        • Kataoka Y.
        • Nakaoku Y.
        • et al.
        The association between the extent of lipidic burden and delta-fractional flow reserve: analysis from coronary physiological and near-infrared spectroscopic measures.
        Cardiovasc Diagn Ther. 2021; 11: 362-372
        • Suzuki N.
        • Asano T.
        • Nakazawa G.
        • et al.
        Clinical expert consensus document on quantitative coronary angiography from the Japanese Association of Cardiovascular Intervention and Therapeutics.
        Cardiovasc Interv Ther. 2020; 35: 105-116
        • Stone G.W.
        • Sabik J.F.
        • Serruys P.W.
        • et al.
        Everolimus-Eluting Stents or Bypass Surgery for Left Main Coronary Artery Disease.
        N Engl J Med. 2016; 375: 2223-2235
      1. Madder RD, Kubo T, Ino Y, et al. Target Lesion Lipid Content Detected by Near-Infrared Spectroscopy After Stenting and the Risk of Subsequent Target Lesion Failure. Arterioscler Thromb Vasc Biol. 2021:ATVBAHA120315617.

        • Nakazawa G.
        • Finn A.V.
        • Joner M.
        • et al.
        Delayed arterial healing and increased late stent thrombosis at culprit sites after drug-eluting stent placement for acute myocardial infarction patients: an autopsy study.
        Circulation. 2008; 118: 1138-1145
        • Kataoka Y.
        • Yasuda S.
        • Miyamoto Y.
        • et al.
        Clinical predictors of atheroma progression despite optimal glycemic control in early-stage diabetic patients with coronary artery disease: Insight from the DIANA study.
        J Atheroscler Thromb. 2014; 21: 509-518
        • Watanabe H.
        • Morimoto T.
        • Shiomi H.
        • et al.
        Impact of Angiographic Residual Stenosis on Clinical Outcomes After New-Generation Drug-Eluting Stents Implantation: Insights From a Pooled Analysis of the RESET and NEXT Trials.
        J Am Heart Assoc. 2018; 7
        • Moreno P.R.
        • Lodder R.A.
        • Purushothaman K.R.
        • Charash W.E.
        • O'Connor W.N.
        • Muller J.E.
        Detection of lipid pool, thin fibrous cap, and inflammatory cells in human aortic atherosclerotic plaques by near-infrared spectroscopy.
        Circulation. 2002; 105: 923-927
        • Waksman R.
        • Di Mario C.
        • Torguson R.
        • et al.
        Identification of patients and plaques vulnerable to future coronary events with near-infrared spectroscopy intravascular ultrasound imaging: a prospective, cohort study.
        Lancet. 2019; 394: 1629-1637
        • Erlinge D.
        • Maehara A.
        • Ben-Yehuda O.
        • et al.
        Identification of vulnerable plaques and patients by intracoronary near-infrared spectroscopy and ultrasound (PROSPECT II): a prospective natural history study.
        The Lancet. 2021; 397: 985-995
        • Yamamoto M.H.
        • Maehara A.
        • Stone G.W.
        • et al.
        2-Year Outcomes After Stenting of Lipid-Rich and Nonrich Coronary Plaques.
        J Am Coll Cardiol. 2020; 75: 1371-1382
        • Ueda Y.
        • Matsuo K.
        • Nishimoto Y.
        • et al.
        In-Stent Yellow Plaque at 1 Year After Implantation Is Associated With Future Event of Very Late Stent Failure: The DESNOTE Study (Detect the Event of Very late Stent Failure From the Drug-Eluting Stent Not Well Covered by Neointima Determined by Angioscopy).
        JACC Cardiovasc Interv. 2015; 8: 814-821
        • Nakazawa G.
        • Nakano M.
        • Otsuka F.
        • et al.
        Evaluation of polymer-based comparator drug-eluting stents using a rabbit model of iliac artery atherosclerosis.
        Circ Cardiovasc Interv. 2011; 4: 38-46
        • Otsuka F.
        • Finn A.V.
        • Yazdani S.K.
        • Nakano M.
        • Kolodgie F.D.
        • Virmani R.
        The importance of the endothelium in atherothrombosis and coronary stenting.
        Nat Rev Cardiol. 2012; 9: 439-453
        • Otsuka F.
        • Vorpahl M.
        • Nakano M.
        • et al.
        Pathology of second-generation everolimus-eluting stents versus first-generation sirolimus- and paclitaxel-eluting stents in humans.
        Circulation. 2014; 129: 211-223
        • Kuramitsu S.
        • Kazuno Y.
        • Sonoda S.
        • et al.
        Vascular response to bioresorbable polymer sirolimus-eluting stent vs. permanent polymer everolimus-eluting stent at 9-month follow-up: an optical coherence tomography sub-study from the CENTURY II trial.
        Eur Heart J Cardiovasc Imaging. 2016; 17: 34-40
      2. Chevalier B, Smits PC, Carrie D, et al. Serial Assessment of Strut Coverage of Biodegradable Polymer Drug-Eluting Stent at 1, 2, and 3 Months After Stent Implantation by Optical Frequency Domain Imaging: The DISCOVERY 1TO3 Study (Evaluation With OFDI of Strut Coverage of Terumo New Drug Eluting Stent With Biodegradable Polymer at 1, 2, and 3 Months). Circ Cardiovasc Interv. 2017;10.

        • Guagliumi G.
        • Shimamura K.
        • Sirbu V.
        • et al.
        Temporal course of vascular healing and neoatherosclerosis after implantation of durable- or biodegradable-polymer drug-eluting stents.
        Eur Heart J. 2018; 39: 2448-2456
        • Lee S.Y.
        • Hur S.H.
        • Lee S.G.
        • et al.
        Optical coherence tomographic observation of in-stent neoatherosclerosis in lesions with more than 50% neointimal area stenosis after second-generation drug-eluting stent implantation.
        Circ Cardiovasc Interv. 2015; 8e001878